Tag Archives: hormone receptor positive

Ibrance plus Faslodex Improves Outcomes in HR+ Breast Cancer

In a Phase 3 Paloma-III study of Pfizer’s CDK4/6 inhibitor (Ibrance – palbociclib) and an estrogen receptor antagonist (Faslodex – fulvestrant), patients receiving the combination had significantly prolonged progression-free survival than women with breast cancer who received Faslodex, alone. Continue reading